Ignite Creation Date:
2024-05-06 @ 1:38 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04071353
Status:
UNKNOWN
Last Update Posted:
2019-08-28
First Post:
2019-08-18
Brief Title:
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C
Sponsor:
Beijing Ditan Hospital
Organization:
Beijing Ditan Hospital
Study Overview
Official Title:
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy in Chronic Hepatitis C Patients
Status:
UNKNOWN
Status Verified Date:
2019-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was a clinical observational cohort study of two-way non-intervention long-term dynamic follow-up Enrolled in the Department of Liver Diseases Beijing Ditan Hospital Capital Medical University with interferon combined with ribavirin PR antiviral therapy PR treatment greater than or equal to 6 months andor direct acting antivirals DAAs In patients with chronic hepatitis C the baseline antiviral treatment and withdrawal follow-up data before the antiviral treatment were collected and the patients were followed up for 3-6 months Clinical data such as clinical biochemistry HCV RNA and serological markers anti-HCV AFP and liver imaging liver ultrasound were collected during the study period At least 144 weeks of observation on the virological response and clinical outcome of anti-viral treatment of chronic hepatitis C the main evaluation index of liver cancer and decompensated liver cirrhosis after stopping the drug and exploring the antiviral treatment of patients Long-term virological response and clinical outcomes clarifying their influencing factors
Detailed Description:
This study was a clinical observational cohort study of two-way non-intervention long-term dynamic follow-up Enrolled in the Department of Liver Diseases Beijing Ditan Hospital Capital Medical University with interferon combined with ribavirin PR antiviral therapy PR treatment greater than or equal to 6 months andor direct acting antivirals DAAs In patients with chronic hepatitis C the baseline antiviral treatment and withdrawal follow-up data before the antiviral treatment were collected and the patients were followed up for 3-6 months Clinical data such as clinical biochemistry HCV RNA and serological markers anti-HCV AFP and liver imaging liver ultrasound were collected during the study period At least 144 weeks of observation on the virological response and clinical outcome of anti-viral treatment of chronic hepatitis C the main evaluation index of liver cancer and decompensated liver cirrhosis after stopping the drug and exploring the antiviral treatment of patients Long-term virological response and clinical outcomes clarifying their influencing factors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None